Today: 7 February 2026
Subscribe
Browse Category

NYSE:IOT News 5 December 2025 - 15 December 2025

Samsara (IOT) Shows Sticky Growth and Operating Leverage as Strategy (MSTR) Buys 10,645 More Bitcoin: Key Updates for Dec. 15, 2025

Samsara (IOT) Shows Sticky Growth and Operating Leverage as Strategy (MSTR) Buys 10,645 More Bitcoin: Key Updates for Dec. 15, 2025

Dec. 15, 2025 — Investors tracking “data economy” winners are watching two very different playbooks this week: Samsara (NYSE: IOT), which sells connected-operations software to fleets and physical enterprises, and Strategy (NASDAQ: MSTR), an analytics software company whose balance sheet has become one of the market’s biggest corporate bets on Bitcoin. On Monday, the broader market is also trying to stabilize after a bruising stretch for parts of the AI trade, with attention turning to key economic data and year-end positioning—an environment where “quality growth” narratives and balance-sheet-driven trades can both move quickly. Reuters Below is a roundup of the
15 December 2025
····
Samsara (IOT) Stock Today: Q3 FY2026 Earnings Beat, First GAAP Profit and a Wave of New $50 Price Targets

Samsara (IOT) Stock Today: Q3 FY2026 Earnings Beat, First GAAP Profit and a Wave of New $50 Price Targets

As of December 5, 2025, Samsara Inc. (NYSE: IOT) has just delivered a landmark quarter: its first ever GAAP profit, another round of 29% top-line growth, and a fresh batch of Wall Street price targets clustered around $50 per share. Yet the stock is still trading in the low $40s and remains well below its 2025 peak, leaving investors debating whether IOT is a high‑growth bargain or a richly priced momentum story. Below is a detailed breakdown of the latest news, forecasts, and analyses around Samsara stock as of December 5, 2025. Samsara stock today: price, range and recent performance
5 December 2025
···

Stock Market Today

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

7 February 2026
AbbVie shares rose 2% to $223.43 Friday, capping a volatile week marked by earnings and drug sales scrutiny. Moody’s upgraded AbbVie’s credit rating to A2, citing strong performance in immunology and neuroscience. Investors remain focused on Skyrizi and Rinvoq growth amid rising competition and recent regulatory filings. Trading volume stayed below average, with the stock still 9% off its 52-week high.
SK hynix stock price slips into Monday after S&P upgrade, tech selloff

SK hynix stock price slips into Monday after S&P upgrade, tech selloff

7 February 2026
SK hynix shares closed at 839,000 won, down 0.36% Friday and 8% for the week, as tech stocks retreated across Asia. S&P Global Ratings upgraded the chipmaker to “BBB+” with a positive outlook, citing strong HBM sales. The KOSPI fell 1.4% Friday, ending a six-week winning streak. Traders await Monday’s Seoul open for signs of further tech weakness.
Bank of America stock jumps 3% into the weekend — what to watch before Monday’s trade

Bank of America stock jumps 3% into the weekend — what to watch before Monday’s trade

7 February 2026
Bank of America shares rose 2.89% Friday to $56.53, tracking a rally in U.S. financial stocks as the Dow closed above 50,000. The bank will redeem its Series DD preferred stock and related depositary shares on March 10 at $1,000 per share. CEO Brian Moynihan donated 100,000 shares on Feb. 4, a regulatory filing showed. Key U.S. jobs and inflation data are due next week after delays.
Oracle stock rebounds from eight-day skid as $20 billion share-sale plan looms

Oracle stock rebounds from eight-day skid as $20 billion share-sale plan looms

7 February 2026
Oracle shares jumped 4.65% to $142.82 Friday, ending an eight-day slide but remaining down 22% since Jan. 27. The company has set up a $20 billion at-the-market stock program and completed a $25 billion senior notes sale to fund cloud expansion. Oracle’s liabilities stood at $174.5 billion as of Nov. 30, 2025, before the new financing. Investors remain focused on dilution risks and the pace of capacity growth.
Go toTop